Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
about
Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapyRespiratory epithelial cells require Toll-like receptor 4 for induction of human beta-defensin 2 by lipopolysaccharideVaccines for Pseudomonas aeruginosa: a long and winding roadClinical applications of pulmonary delivery of antibioticsThe galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung.Lung infections associated with cystic fibrosis.Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.Release of cystic fibrosis airway inflammatory markers from Pseudomonas aeruginosa-stimulated human neutrophils involves NADPH oxidase-dependent extracellular DNA trap formation.The Pseudomonas aeruginosa AlgZR two-component system coordinates multiple phenotypes.Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophilsThe complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosaNeutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.Clinical significance of microbial infection and adaptation in cystic fibrosis.Modulation of cystic fibrosis lung disease by variants in interleukin-8.Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.Multidimensional clinical phenotyping of an adult cystic fibrosis patient populationRelationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project.Association of tumour necrosis factor alpha variants with the CF pulmonary phenotypeInfection control in cystic fibrosis.Inflammatory markers of lung disease in adult patients with cystic fibrosis.Microsphere bead arrays and sequence validation of 5/7/9T genotypes for multiplex screening of cystic fibrosis polymorphisms.Future directions in early cystic fibrosis lung disease research: an NHLBI workshop reportChange in Pseudomonas aeruginosa prevalence in cystic fibrosis adults over time.Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis.Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers.Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosisType III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis.Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.Biomarkers for cystic fibrosis drug development.Role of alginate O acetylation in resistance of mucoid Pseudomonas aeruginosa to opsonic phagocytosis.Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.Evolution and diversification of Pseudomonas aeruginosa in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection.Resistance to Pseudomonas aeruginosa chronic lung infection requires cystic fibrosis transmembrane conductance regulator-modulated interleukin-1 (IL-1) release and signaling through the IL-1 receptor.Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency.Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis.Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.
P2860
Q24650612-2A52C1CE-B834-48A3-8C94-71E891E1A072Q24813071-BB6A3280-78B2-4112-A7A4-CC10F977D297Q26852817-4A5D2928-14B3-48BB-B3F0-BB96252D288AQ26996053-F7E73C5B-68CE-4C17-92DB-484B93D3D3CFQ28492530-C203741D-445C-4F6C-9859-BE815E3BA964Q30080000-A134ECED-39C8-4D88-AB8A-6DC19F978496Q30413773-186A1321-4E7B-4857-8A20-4C5B71D5AE37Q33654992-B12AD787-09B1-4C35-8E95-7F068ACE07DBQ33780971-825514F2-F5FC-4C90-89B0-1FA82453F770Q33788110-48F7C968-FF01-4A56-B767-4491C6E1A65FQ33856134-6D705FC8-0D06-4301-A461-5EC3965E2EFCQ34016539-8F1962C2-7A9C-473F-AA70-4EDEF76C6809Q34491552-A3890DE7-4F5D-475E-B126-D5532B915A1EQ34629056-0FB8798C-66C4-4C4C-8D77-8D41D1985D41Q35127240-A8516BC3-546B-45F4-B650-DBFF3F4C7D21Q35139384-E7D37850-8FB5-4BBA-B196-9A55F7AFD2E4Q35230948-B0E43FDF-B594-465C-8A2D-C1BC54100E7AQ35535262-8AA87A72-A50E-4D05-A826-34CF284AABE5Q35537601-F01ACD06-659D-4E8D-879C-2481AB52DC6AQ35545544-554EF533-2900-4A1C-9D73-A1DAD85AC208Q35749974-4791C6E9-99A3-4604-A72B-75E86EBA4EA0Q35789769-E8C43FB5-4544-4EE8-9687-04BA9CFCAE17Q35988949-F0ED82AE-5221-4CF6-A6BA-560921F1A430Q36215326-4AAE7044-2CA2-4510-BC17-759CDE554B86Q36968815-9411EF61-5A1D-44AE-83A6-BC9AA1F4D810Q36980425-053D6F36-B5EF-4BA2-BC90-B5BB03ADE61BQ36999096-79173F9C-8938-4B85-934A-9564A99AEE2CQ37125716-ADE6DF63-958C-40F2-86F8-07851F8F61ACQ37366880-9830ED1D-146A-4B19-BB5B-1DD82DEE0D43Q37597434-3230E291-2E69-4DDC-BB24-36A67E9F8201Q37727308-33508CF3-A5D8-47CA-B33F-AF7138E7F088Q38755600-532DE49A-FDB2-499E-A941-70D49674562CQ39519011-2DB863F9-B02F-49B5-B14E-0380886005CAQ39651481-BE013C4B-86DF-48AE-9F69-CF475B1B074EQ39997040-F901DB17-ACC1-4F05-AF71-D7F90B07273AQ40174308-1DC31DC9-DF59-40C8-BDCD-B0831E016C7AQ43084409-8168E8DC-B760-4F7A-81A0-3E028C17F7F7Q43153453-8241F43B-8F2B-4B3E-97A8-297171727B11Q47103711-3A7B6FB6-F225-4D6D-B3E6-5B3314B2F7D6Q49445381-8C217F94-794E-4D3C-927E-D85B9B6ED0AA
P2860
Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
description
1999 nî lūn-bûn
@nan
1999 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@ast
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@en
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@nl
type
label
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@ast
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@en
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@nl
prefLabel
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@ast
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@en
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@nl
P2093
P2860
P1476
Pulmonary outcome in cystic fi ...... and only modestly by genotype.
@en
P2093
C J Gerard
D P Nichols
D Zurakowski
P2860
P304
P407
P577
1999-09-01T00:00:00Z